HDL-C: Does it matter? An update on novel HDL-directed pharmaco-therapeutic strategies

International Journal of Cardiology

Volumn 167, Issue 3, 2013, Pages 646-655

  Gadi, Ramprasad ^a   Amanullah, Aman ^a   Figueredo, Vincent M ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cardiovascular; Coronary artery disease; HDL C therapeutics; High density lipoprotein (HDL C)

Indexed keywords

ANACETRAPIB; APOLIPOPROTEIN A1; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; ENDOTHELIAL LIPASE INHIBITOR; ENZYME INHIBITOR; EZETIMIBE; FIBRIC ACID DERIVATIVE; FISH OIL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER X RECEPTOR AGONIST; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; RECOMBINANT HIGH DENSITY LIPOPROTEINCHOLESTEROL; RECOMBINANT PROTEIN; ROSUVASTATIN; RVX 208; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APHERESIS; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BEDTIME DOSAGE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PERFORMANCE; CETP GENE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CLINICAL TRIAL (TOPIC); DIGESTIVE SYSTEM DISEASE; DNA POLYMORPHISM; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; ETHNIC GROUP; FISH; FLUSHING; GALLSTONE; GASTROESOPHAGEAL REFLUX; GENE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIPOLYSIS; LIVER TOXICITY; MILANO; MORBIDITY; MYOPATHY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVERSE CHOLESTEROL TRANSPORT; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SUPPLEMENTATION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT INDICATION; UPPER GASTROINTESTINAL DISTRESS;

CARDIOVASCULAR; CORONARY ARTERY DISEASE; HDL-C THERAPEUTICS; HIGH DENSITY LIPOPROTEIN (HDL-C);

AGE OF ONSET; ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NIACIN; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 84880919554     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.05.052     Document Type: Review

References (117)

1. American Heart Association Heart disease and stroke statistics - 2012 update 2012 American Heart Association Dallas (TX)
2. S.C. Smith, J. Allen, and S.N. Blair AHA/ACC guidelines for secondary prevention for patients with coronary artery disease other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute Circulation 113 2006 2363e72
3. D. Duffy, and D.J. Rader Update on strategies to increase HDL quantity and function Nat Rev Cardiol 6 2009 455e63
4. M.H. Davidson, and P.P. Toth High-density lipoprotein metabolism: potential therapeutic targets Am J Cardiol 100 11A 2007 n32e40
5. M.H. Davidson Focus on HDL as a therapeutic target for CAD risk reduction Am J Cardiol 104 Suppl. 10 2009 1Ee2E
6. S. Hulley, P. Ashman, L. Kuller, N. Lasser, and R. Sherwin HDL-cholesterol levels in the Multiple Risk Factor Intervention Trial (MRFIT) by the MRFIT Research Group 1,2 Lipids 14 1979 119 123
7. A. Keys Alpha lipoprotein (HDL) cholesterol in the serum and the risk of coronary heart disease and death Lancet 2 1980 603 606
8. W.A. Ghali, and N. Rodondi HDL cholesterol and cardiovascular risk BMJ 338 2009 a3065
9. S. Fazio, and M.F. Linton Elevated high-density lipoprotein (HDL) levels due to hepatic lipase mutations do not reduce cardiovascular disease risk: another strike against the HDL dogma J Clin Endocrinol Metab 94 2009 1081 1083
10. S. Fazio, and M.F. Linton Sorting out the complexities of reverse cholesterol transport: CETP polymorphisms, HDL, and coronary disease J Clin Endocrinol Metab 91 2006 3273 3275
11. S. Fazio, and M.F. Linton Apolipoprotein AI as therapy for atherosclerosis: does the future of preventive cardiology include weekly injections of the HDL protein? Mol Interv 3 2003 436 440
12. G. Franceschini, C.R. Sirtori, A. Capurso II, K.H. Weisgraber, and R.W. Mahley A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family J Clin Invest 66 1980 892 900
13. B. Agerholm-Larsen, B.G. Nordestgaard, R. Steffensen, G. Jensen, and A. Tybjaerg-Hansen Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene Circulation 101 2000 1907 1912
14. S.E. Borggreve, H.L. Hillege, and G.M. Dallinga-Thie High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides Eur Heart J 28 2007 1012 1018
15. Y. Saito Is cholesteryl ester transfer protein (CETP) deficiency atherogenic in familial hypercholesterolemia Intern Med 37 1998 495 496
16. S. Zhong, D.S. Sharp, and J.S. Grove Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels J Clin Invest 97 1996 2917 2923
17. S.E. Borggreve, H.L. Hillege, and B.H. Wolffenbuttel An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study J Clin Endocrinol Metab 91 2006 3382 3388
18. T.H. Johannsen, P.R. Kamstrup, and R.V. Andersen Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease J Clin Endocrinol Metab 94 2009 1264 1273
19. E.M. deGoma, R.L. deGoma, and D.J. Rader Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches J Am Coll Cardiol 51 2008 2199 2211
20. K.A. Rye, C.A. Bursill, G. Lambert, F. Tabet, and P.J. Barter The metabolism and anti-atherogenic properties of HDL J Lipid Res 50 Suppl. 2009 S195 S200
21. D. Sviridov, N. Mukhamedova, A.T. Remaley, J. Chin-Dusting, and P. Nestel Antiatherogenic functionality of high density lipoprotein: how much versus how good J Atheroscler Thromb 15 2008 52 62
22. B.J. Ansell, M. Navab, and S. Hama Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment Circulation 108 2003 2751 2756
23. W.A. van der Steeg, I. Holme, and S.M. Boekholdt High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies J Am Coll Cardiol 51 2008 634 642
24. G. Assmann, A. von Eckardstein, and H. Funke High density lipoproteins, reverse transport of cholesterol, and coronary artery disease. Insights from mutations Circulation 87 1993 III28 III34
25. M.P. Petraki, P.T. Mantani, and A.D. Tselepis Recent advances on the antiatherogenic effects of HDL-derived proteins and mimetic peptides Curr Pharm Des 15 2009 3146 3166
26. B.J. Ansell, G.C. Fonarow, and A.M. Fogelman The paradox of dysfunctional high-density lipoprotein Curr Opin Lipidol 18 2007 427 434
27. S. Acton, A. Rigotti, K.T. Landschulz, S. Xu, H.H. Hobbs, and M. Krieger Identification of scavenger receptor SR-BI as a high density lipoprotein receptor Science 271 1996 518 520
28. R. McPherson, and Y. Marcel Role of cholesteryl ester transfer protein in reverse cholesterol transport Clin Cardiol 14 1991 I31 I34
29. J.H. Graversen, G. Castro, and A. Kandoussi A pivotal role of the human kidney in catabolism of HDL protein components apolipoprotein A-I and A-IV but not of A-II Lipids 43 2008 467 470
30. S.M. Hammad, J.L. Barth, C. Knaak, and W.S. Argraves Megalin acts in concert with cubilin to mediate endocytosis of high density lipoproteins J Biol Chem 275 2000 12003 12008
31. V.I. Zannis, A. Chroni, and M. Krieger Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL J Mol Med 84 2006 276 294
32. I. Lorenzi, A. von Eckardstein, S. Radosavljevic, and L. Rohrer Lipidation of apolipoprotein A-I by ATP-binding cassette transporter (ABC) A1 generates an interaction partner for ABCG1 but not for scavenger receptor BI Biochim Biophys Acta 1781 2008 306 313
33. A.M. Vaughan, and J.F. Oram ABCA1 and ABCG1 or ABCG4 act sequentially to remove cellular cholesterol and generate cholesterol-rich HDL J Lipid Res 47 2006 2433 2443
34. P.G. Yancey, W.G. Jerome, and H. Yu Severely altered cholesterol homeostasis in macrophages lacking apoE and SR-BI J Lipid Res 48 2007 1140 1149
35. T. Vaisar, S. Pennathur, and P.S. Green Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL J Clin Invest 117 2007 746 756
36. M. Navab, G.M. Ananthramaiah, and S.T. Reddy The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL J Lipid Res 45 2004 993 1007
37. National Cholesterol Education Panel Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143e421
38. M.H. Davidson, and R.S. Rosenson Novel targets that affect high-density lipoprotein metabolism: the next frontier Am J Cardiol 104 10 Suppl. 2009 52Ee7E
39. Study of Coronary Atheroma by Intravascular Ultrasound: effect of Rosuvastatin Versus Atorvastatin (SATURN). Available at: http://clinicaltrials. gov/ct2/ show/NCT00620542. Accessed October 30, 2010
40. K.G. Berge, and P.L. Canner Coronary drug project: experience with niacin. Coronary Drug Project Research Group Eur J Clin Pharmacol 40 Suppl. 1 1991 S49e51
41. V.S. Kamanna, and M.L. Kashyap Mechanism of action of niacin on lipoprotein metabolism Curr Atheroscler Rep 2 2000 36e46
42. N.B. Pike Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid J Clin Invest 115 12 2005 3400e3
43. K. Cheng, T.J. Wu, and K.K. Wu Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans Proc Natl Acad Sci U S A 103 2006 6682e7
44. J.R. Guyton, and H.E. Bays Safety considerations with niacin therapy Am J Cardiol 99 2007 22C 31C
45. A.J. Taylor, L.E. Sullenberger, and H.J. Lee Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2 Circulation 110 2004 3512e7
46. ClinicalTrials.gov Niacin plus statin to prevent vascular events [online], http://clinicaltrials.gov/ct2/show/NCT00120289 2010
47. ClinicalTrials.gov Treatment of HDL to reduce the incidence of vascular events HPS2-THRIVE [online], http://clinicaltrials.gov/ct2/show/NCT00461630 2010
48. P.H. Jones, K. Cusi, and M.H. Davidson Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials Am J Cardiovasc Drugs 10 2010 73e84
49. M.H. Davidson, M.W. Rooney, and J. Drucker Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study Clin Ther 12 2009 2824e38
50. J.J. Badimon, L. Badimon, and V. Fuster Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit J Clin Invest 85 1990 1234 1241
51. G. Chiesa, E. Monteggia, and M. Marchesi Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks Circ Res 90 2002 974 980
52. C. Parolini, M. Marchesi, and P. Lorenzon Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging J Am Coll Cardiol 51 2008 1098 1103
53. J.J. Badimon, L. Badimon, A. Galvez, R. Dische, and V. Fuster High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits Lab Invest 60 1989 455 461
54. P.K. Shah, J. Nilsson, and S. Kaul Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice Circulation 97 1998 780 785
55. Y. Zhang, I. Zanotti, and M.P. Reilly Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo Circulation 108 2003 661 663
56. P.J. Barter, S. Nicholls, and K.A. Rye Antiinflammatory properties of HDL Circ Res 95 2004 764 772
57. S.J. Nicholls, G.J. Dusting, and B. Cutri Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits Circulation 111 2005 1543 1550
58. S.E. Nissen, T. Tsunoda, and E.M. Tuzcu Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 2003 2292 2300
59. C.R. Sirtori, L. Calabresi, and G. Franceschini Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study Circulation 103 2001 1949 1954
60. S. Kaul, V. Rukshin, and R. Santos Intramural delivery of recombinant apolipoprotein A-IMilano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries Circulation. 107 20 2003 2551 2554
61. S. Ameli, A. Hultgardh-Nilsson, and B. Cercek Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits Circulation 90 1994 1935 1941
62. P.K. Shah, J. Yano, and O. Reyes High-dose recombinant apolipoprotein A-I(Milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization Circulation 103 2001 3047 3050
63. J.C. Tardif, J. Gregoire, and P.L. L'Allier Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial JAMA 297 15 2007 1675e82
64. J.A. Shaw, A. Bobik, and A. Murphy Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque Circ Res 103 10 2008 1084e91
65. R. Waksman, R. Torguson, and K.M. Kent A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome J Am Coll Cardiol 55 2010 2727 2735
66. D. Bailey, R. Jahagirdar, and A. Gordon RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo J Am Coll Cardiol 55 2010 2580 2589
67. S. Tunaru, J. Kero, and A. Schaub PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect Nat Med 9 2003 352 355
68. D. Maccubbin, M.J. Koren, and M. Davidson Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease Am J Cardiol 104 2009 74 81
69. J.R. Guyton, and H.E. Bays Safety considerations with niacin therapy [see comment] Am J Cardiol 99 6A 2007 2231-2231C
70. J. Hanson, A. Gille, and S. Zwykiel Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice J Clin Invest 120 2010 2910 2919
71. R.L. Dunbar, and J.M. Gelfand Seeing red: flushing out instigators of niacin-associated skin toxicity J Clin Invest 120 2010 2651 2655
72. B.J. Van Lenten, A.C. Wagner, and G.M. Anantharamaiah Apolipoprotein A-I mimetic peptides Curr Atheroscler Rep 11 2009 52 57
73. M. Navab, G.M. Ananthramaiah, and S.T. Reddy The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL J Lipid Res 45 2004 993 1007
74. G.M. Anantharamaiah, V.K. Mishra, and D.W. Garber Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides J Lipid Res 48 2007 1915 1923
75. L.T. Bloedon, R. Dunbar, and D. Duffy Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients J Lipid Res 49 2008 1344 1352
76. A.R. Tall The effects of cholesterol ester transfer protein inhibition on cholesterol efflux Am J Cardiol 104 Suppl. 2009 39Ee45E
77. P.J. Barter, M. Caulfield, and M. Eriksson Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
78. M.L. Bots, F.L. Visseren, and G.W. Evans Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial Lancet 370 2007 153 160
79. S.J. Nicholls, E.M. Tuzcu, D.M. Brennan, J.C. Tardif, and S.C. Nissen Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 118 2008 2506 2514
80. F. Matsuura, N. Wang, W. Chen, X.C. Jiang, and A.R. Tall HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway J Clin Invest 116 2006 1435 1442
81. M.J. Forrest, D. Bloomfield, and R.J. Briscoe Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone Br J Pharmacol 154 2008 1465 1473
82. M. Ishigami, S. Yamashita, and N. Sakai Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins J Biochem 116 1994 257 262
83. L. Yvan-Charvet, F. Matsuura, and N. Wang Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL Arterioscler Thromb Vasc Biol 27 2007 1132 1138
84. L. Yvan-Charvet, J. Kling, and T. Pagler Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib Arterioscler Thromb Vasc Biol 30 2010 1430 1438
85. H. Tanigawa, J.T. Billheimer, and J. Tohyama Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport Circulation 116 2007 1267 1273
86. M. Vergeer, and E.S. Stroes The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors Am J Cardiol 104 10 Suppl. 2009 32E 38E
87. E.J. Niesor, C. Magg, and N. Ogawa Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport J Lipid Res 51 2010 3443 3454
88. G.J. de Grooth, J.A. Kuivenhoven, and A.F. Stalenhoef Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study Circulation 105 2002 2159 2165
89. J.A. Kuivenhoven, G.J. de Grooth, and H. Kawamura Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia Am J Cardiol 95 2005 1085 1088
90. E.A. Stein, E.M. Roth, and J.M. Rhyne Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial Eur Heart J 31 2010 480 488
91. ClinicalTrials.gov A study of the effect of dalcetrapib on artherosclerotic disease in patients with coronary artery disease [online], http://clinicaltrials.gov/ct2/show/NCT01059682 2010
92. ClinicalTrials.gov A study of the effect of RO4607381 on atherosclerotic plaque in patients with coronary heart disease [online], http://clinicaltrials. gov/ct2/show/NCT00655473 2010
93. ClinicalTrials.gov A study assessing the effect of RO4607381 on vascular function in patients with coronary heart disease (CHD) or CHD-risk equivalent patients [online], http://clinicaltrials.gov/ct2/show/NCT00655538 2010
94. ClinicalTrials.gov A study of RO4607381 in stable coronary heart disease patients with recent acute coronary syndrome [online], http://clinicaltrials. gov/ct2/show/NCT00658515 2010
95. M. Ranalletta, K.K. Bierilo, and Y. Chen Biochemical characterization of cholesteryl ester transfer protein inhibitors J Lipid Res 51 2010 2739 2752
96. R. Krishna, M.S. Anderson, and A.J. Bergman Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies Lancet 370 2007 1907 1914
97. D. Bloomfield, G.L. Carlson, and A. Sapre Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients Am Heart J 157 2009 352 360
98. C.P. Cannon, H.M. Dansky, and M. Davidson Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib Am Heart J 158 2009 513 519
99. C.P. Cannon, S. Shah, and H.M. Dansky Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
100. ClinicalTrials.gov REVEAL: Randomized EValuation of the Effects of Anacetrapib through Lipid-modification [online], http://clinicaltrials.gov/ct2/ show/NCT01252953 2010
101. D.J. Rader Liver X receptor and farnesoid X receptor as therapeutic targets Am J Cardiol 100 Suppl. 1 2007 S15 S19
102. E. Rigamonti, L. Helin, and S. Lestavel Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages Circ Res 97 2005 682 689
103. P. Costet, Y. Luo, N. Wang, and A.R. Tall Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor J Biol Chem 275 2000 28240 28245
104. L.R. Brunham, J.K. Kruit, and J. Iqbal Intestinal ABCA1 directly contributes to HDL biogenesis in vivo J Clin Invest 116 2006 1052 1062
105. A. Grefhorst, B.M. Elzinga, and P.J. Voshol Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles J Biol Chem 277 2002 34182 34190
106. S.Y. Choi, K. Hirata, T. Ishida, T. Quertermous, and A.D. Cooper Endothelial lipase: a new lipase on the block J Lipid Res 43 2002 1763 1769
107. T. Ishida, S. Choi, and R.K. Kundu Endothelial lipase is a major determinant of HDL level J Clin Invest 111 2003 347 355
108. W. Jin, J.S. Millar, U. Broedl, J.M. Glick, and D.J. Rader Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo J Clin Invest 111 2003 357 362
109. M. Jaye, K.J. Lynch, and J. Krawiec A novel endothelial-derived lipase that modulates HDL metabolism Nat Genet 21 1999 424 428
110. A.C. Edmondson, R.J. Brown, and S. Kathiresan Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans J Clin Invest 119 2009 1042 1050
111. K.O. Badellino, M.L. Wolfe, M.P. Reilly, and D.J. Rader Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis PLoS Med 3 2006 e22
112. K.O. Badellino, M.L. Wolfe, M.P. Reilly, and D.J. Rader Endothelial lipase is increased in vivo by inflammation in humans Circulation 117 2008 678 685
113. N.P. Tang, LS. Wang, and L. Yang Protective effect of an endothelial lipase gene variant on coronary artery disease in a Chinese population J Lipid Res 49 2008 369 375
114. M. Vergeer, D.M. Cohn, and S.M. Boekholdt Lack of association between common genetic variation in endothelial lipase (LIPG) and the risk for CAD and DVT Atherosclerosis 211 2010 558 564
115. M.K. Jensen, E.B. Rimm, and K.J. Mukamal The T111I variant in the endothelial lipase gene and risk of coronary heart disease in three independent populations Eur Heart J 30 2009 1584 1589
116. R.J. Brown, W.R. Lagor, and S. Sankaranaravanan Impact of combined deficiency of hepatic lipase and endothelial lipase on the metabolism of both high-density lipoproteins and apolipoprotein B-containing lipoproteins Circ Res 107 2010 357 364
117. K.B. Goodman, M.J. Bury, and M. Cheung Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors Bioorg Med Chem Lett 19 2009 27 30